Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 5.6% – What’s Next?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s stock price rose 5.6% during trading on Wednesday . The company traded as high as $113.49 and last traded at $110.55. Approximately 16,636 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 272,438 shares. The stock had previously closed at $104.67.

Analyst Ratings Changes

A number of research firms recently issued reports on PVLA. BTIG Research raised their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Wall Street Zen cut Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Truist Financial set a $210.00 target price on Palvella Therapeutics in a report on Tuesday, February 24th. Mizuho upped their price target on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Stephens reiterated an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $199.53.

Palvella Therapeutics Trading Up 5.8%

The business has a 50 day moving average price of $121.15 and a 200-day moving average price of $107.27. The firm has a market capitalization of $1.59 billion, a PE ratio of -26.55 and a beta of -0.14.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, equities research analysts forecast that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Palvella Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV purchased a new position in Palvella Therapeutics in the first quarter valued at about $28,000. Group One Trading LLC boosted its stake in shares of Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics in the 3rd quarter worth approximately $36,000. China Universal Asset Management Co. Ltd. purchased a new position in Palvella Therapeutics in the 4th quarter valued at approximately $167,000. Finally, Keybank National Association OH acquired a new position in Palvella Therapeutics during the first quarter worth $228,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.